Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome

Bibliography:

• Mozaffari S, Rahimi R, Abdollahi M. Implications of melatonin therapy in irritable bowel syndrome: a systematic review. Curr Pharm Des 2010;16:3646-55
   PubMed Web of Science ®Google Scholar
• Rahimi R, Abdollahi M. Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol 2012;18:589-600
   PubMed Web of Science ®Google Scholar
• Bassett JT, Cash BD. A review of irritable bowel syndrome and an update on therapeutic approaches. Expert Opin Pharmacother 2008;9:1129-43
   PubMed Web of Science ®Google Scholar
• Sainsbury A, Ford AC. Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therap Adv Gastroenterol 2011;4:115-27
   PubMedGoogle Scholar
• Ford AC, Talley NJ, Spiegel BMR, Effect of fibre, antispasmodics, and peppermint oil in irritable bowel syndrome: systematic review and meta-analysis. Br Med J 2008;337:1388-92
   Google Scholar
• Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010;16:547-53
   PubMed Web of Science ®Google Scholar
• Drossman DA, Toner BB, Whitehead WE, Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31
   PubMed Web of Science ®Google Scholar
• Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010;16:4504-14
   PubMed Web of Science ®Google Scholar
• Salari P, Nikfar S, Abdollahi M. A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets 2011;11:3-14
   Google Scholar
• Nikfar S, Rahimi R, Rahimi F, Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008;51:1775-80
   PubMed Web of Science ®Google Scholar
• Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci 2010;6:49-55
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-19
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chatterjee S, Chow EJ, Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006;51:1297-301
   PubMed Web of Science ®Google Scholar
• Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012;107:28-35
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32
   PubMed Web of Science ®Google Scholar
• Yang J, Lee HR, Low K, Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008;53:169-74
   PubMed Web of Science ®Google Scholar
• Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2012;13:433-40
   PubMed Web of Science ®Google Scholar
• Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-6
   PubMedGoogle Scholar
• Taylor DN, McKenzie R, Durbin A, Systemic Pharmacokinetics of Rifaximin in Volunteers with Shigellosis. Antimicrob Agents Chemother 2008;52:1179-81
   PubMed Web of Science ®Google Scholar
• Pimentel M, Park S, Mirocha J, The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145:557-63
   PubMed Web of Science ®Google Scholar
• Schey R, Rao SS. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. Expert Rev Gastroenterol Hepatol 2011;5:461-4
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008;30:884-901
   PubMed Web of Science ®Google Scholar
• Mangel AW, Bornstein JD, Hamm LR, Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:239-49
   PubMed Web of Science ®Google Scholar
• Atkinson W, Lockhart S, Whorwell PJ, Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43
   PubMed Web of Science ®Google Scholar
• Lee KJ, Kim NY, Kwon JK, Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011;23:1098-104
   PubMed Web of Science ®Google Scholar
• Matsueda K, Harasawa S, Hongo M, A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008;43:1202-11
   PubMed Web of Science ®Google Scholar
• Matsueda K, Harasawa S, Hongo M, A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-35
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54
   PubMed Web of Science ®Google Scholar
• Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67:82-9
   PubMed Web of Science ®Google Scholar
• Lindström E, Ravnefjord A, Brusberg M, The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats. J Pharmacol Exp Ther 2009;329:1048-55
   PubMed Web of Science ®Google Scholar
• Brown PM, Drossman DA, Wood AJ, The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipatingirritable bowel syndrome. Gastroenterology 2011;141:507-16
   PubMed Web of Science ®Google Scholar
• Kadokura T, den Adel M, Krauwinkel WJ, The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects. Eur J Clin Pharmacol 2008;64:691-5
   PubMed Web of Science ®Google Scholar
• Tabata H, Matsuzawa T, Hanada T, Acute, subacute and chronic oral toxicity studies of the new serotonin (5-HT) 3-receptor antagonist ramosetron in beagle dogs. Arzneimittelforschung 1995;45:760-6
   PubMed Web of Science ®Google Scholar
• Niwa T, Yamamoto S, Saito M, Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull 2006;29:1931-5
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35:745-67
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-28
   PubMed Web of Science ®Google Scholar
• Camilleri M, Beyens G, Kerstens R, Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256-e117
   PubMed Web of Science ®Google Scholar
• Tran HT, Tran PH, Lee BJ. New findings on melatonin absorption and alterations by pharmaceutical excipients using the Ussing chamber technique with mounted rat gastrointestinal segments. Int J Pharm 2009;378:9-16
   PubMedGoogle Scholar
• Mistraletti G, Sabbatini G, Taverna M, Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res 2010;48:142-7
   PubMed Web of Science ®Google Scholar
• Gooneratne NS, Edwards AY, Zhou C, Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res 2012;52:437-45
   PubMed Web of Science ®Google Scholar
• Aygün D, Kaplan S, Odaci E, Toxicity of non-steroidal anti-inflammatory drugs: a review of melatonin and diclofenac sodium association. Histol Histopathol 2012;27:417-36
   PubMed Web of Science ®Google Scholar
• Jahnke G, Marr M, Myers C, Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 1999;50:271-9
   PubMed Web of Science ®Google Scholar
• Wiechmann AF, Chignell CF, Roberts JE. Influence of dietary melatonin on photoreceptor survival in the rat retina: an ocular toxicity study. Exp Eye Res 2008;86:241-50
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Zavarzina NY, Zabezhinski MA, Melatonin increases both life span and tumor incidence in female CBA mice. J Gerontol A BiolSci Med Sci 2001;56:B311-23
   PubMed Web of Science ®Google Scholar
• Buscemi N, Vandermeer B, Hooton N, Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006;332:385-93
   PubMed Web of Science ®Google Scholar
• Buscemi N, Vandermeer B, Hooton N, The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005;20:1151-8
   PubMed Web of Science ®Google Scholar
• Salari P, Abdollahi M. Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J Gastroenterol 2011;17:4251-7
   PubMed Web of Science ®Google Scholar
• Gale JD, Houghton LA. Alpha 2 delta ligands, gabapentin and pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome. Front Pharmacol 2011;2:28
   PubMed Web of Science ®Google Scholar
• Houghton LA, Fell C, Whorwell PJ, Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007;56:1218-25
   PubMed Web of Science ®Google Scholar
• Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechano sensitivity and increases rectal compliance in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:981-8
   PubMed Web of Science ®Google Scholar
• Camilleri M. alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome? Gut 2007;56:1337-8
   PubMedGoogle Scholar
• Diop L, Raymond F, Fargeau H, Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J Pharmacol Exp Ther 2002;302:1013-22
   PubMed Web of Science ®Google Scholar
• Ravnefjord A, Brusberg M, Larsson H, Effects of pregabalin on visceral pain responses and colonic compliance in rats. Br J Pharmacol 2008;155:407-16
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Wesche D, Miller R, A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010;49:661-9
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006;45:1061-75
   PubMed Web of Science ®Google Scholar
• Murphy NG, Mosher L. Severe myoclonus from pregabalin (Lyrica) due to chronic renal insufficiency. Clin Toxicol 2008;46:594
   Google Scholar
• Yoo L, Matalon D, Hoffman RS, Goldfarb DS. Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure. Am J Kidney Dis 2009;54:1127-30
   PubMed Web of Science ®Google Scholar
• Bialer M. The pharmacokinetics and interactions of new antiepileptic drugs: an overview. Ther Drug Monit 2005;27:722-6
   PubMed Web of Science ®Google Scholar
• Delvaux M, Louvel D, Lagier E, The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999;116:38-45
   PubMed Web of Science ®Google Scholar
• Delvaux M, Beck A, Jacob J, Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:237-46
   PubMed Web of Science ®Google Scholar
• Camilleri M. Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 2008;20:971-9
   PubMed Web of Science ®Google Scholar
• Hubbard CS, Labus JS, Bueller J, Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. J Neurosci 2011;31:12491-500
   PubMed Web of Science ®Google Scholar
• Sweetser S, Camilleri M, Linker Nord SJ, Do corticotropin releasing factor -1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J PhysiolGastrointest Liver Physiol 2009;296:G1299-306
   PubMed Web of Science ®Google Scholar
• Cremonini F, Camilleri M, McKinzie S, Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005;100:652-63
   PubMed Web of Science ®Google Scholar
• Zhou L, Dockens RC, Liu-Kreyche P, In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist. Drug Metab Dispos 2012;40:1093-103
   PubMed Web of Science ®Google Scholar
• Persiani S, D'Amato M, Jakate A, Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet 2006;45:1177-88
   PubMed Web of Science ®Google Scholar
• Persiani S, D'Amato M, Makovec F, Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int J Clin Pharmacol Ther 2002;40:198-206
   PubMed Web of Science ®Google Scholar
• Roy P, Wangsa J, Patel A, The single-dose pharmacokinetics of the novel CCK1 receptor antagonist, dexloxiglumide, are not influenced by age and gender. Int J Clin Pharmacol Ther 2005;43:444-51
   PubMed Web of Science ®Google Scholar
• Lunsford TN, Harris LA. Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Women's Health 2010;2:361-74
   PubMedGoogle Scholar
• Schey R, Rao SS. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci 2011;56:1619-25
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha AE, Ueno R, Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastricsensory, and motor functions in healthy volunteers. Am J PhysiolGastrointest Liver Physiol 2006;290:G942-7
   PubMed Web of Science ®Google Scholar
• Fukudo S, Hongo M, Kaneko H, Ueno R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011;23:544-e205
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF, Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41
   PubMed Web of Science ®Google Scholar
• Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351-61
   PubMed Web of Science ®Google Scholar
• Chey WD, Drossman DA, Johanson JF, Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35:587-99
   PubMed Web of Science ®Google Scholar
• Johanson JF, Drossman DA, Panas R, Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-96
   PubMed Web of Science ®Google Scholar
• Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-7
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Palsson OS, Gangarosa L, Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011;23:944-e400
   PubMed Web of Science ®Google Scholar
• Eutamene H, Bradesi S, Larauche M, Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312-e84
   PubMed Web of Science ®Google Scholar
• Lee N, Wald A. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide. Expert Opin Drug Metab Toxicol 2011;7:651-9
   PubMed Web of Science ®Google Scholar
• Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011;5:253-66
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Kurtz CB, Macdougall JE, Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Schneier HA, Shiff SJ, Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-36
   PubMed Web of Science ®Google Scholar
• Andresen V, Camilleri M, Busciglio IA, Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8
   PubMed Web of Science ®Google Scholar
• Rao S, Lembo A, Shiff SJ, Efficacy and safety of once daily linaclotide in patients with irritable bowel syndrome with constipation: a 12-week, randomized, double-blind, placebo-controlled phase 3 trial followed by a 4-week randomized withdrawal period. Gastroenterology 2011;140:S138
   Web of Science ®Google Scholar
• Hellström PM, Hein J, Bytzer P, Clinical trial: the glucagon-like peptide-1analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009;29:198-206
   PubMed Web of Science ®Google Scholar
• Camilleri M, Vazquez-Roque M, Iturrino J, Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303:G120-8
   PubMed Web of Science ®Google Scholar
• Clavé P, Acalovschi M, Triantafillidis JK, Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011;34:432-42
   PubMed Web of Science ®Google Scholar
• Evangelista S. Otilonium bromide: a selective spasmolytic for the gastrointestinal tract. J Int Med Res 1999;27:207-22
   PubMed Web of Science ®Google Scholar
• La JH, Kim TW, Sung TS, Increase in neurokinin-1 receptor-mediated colonic motor response in a rat model of irritable bowel syndrome. World J Gastroenterol 2005;11:237-41
   PubMed Web of Science ®Google Scholar
• Zakko S, Barton G, Weber E, Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011;33:1311-21
   PubMed Web of Science ®Google Scholar
• Tillisch K, Labus J, Nam B, Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther 2012;35:360-7
   Google Scholar
• Hosseini A, Nikfar S, Abdollahi M. Probiotics use to treat irritable bowel syndrome. Expert Opin Biol Ther 2012;12(10):1323-34
   PubMed Web of Science ®Google Scholar
• Hosseini A, Nikfar S, Abdollahi M. Are probiotics effective in management of irritable bowel syndrome? Arch Med Sci 2012;8(3):403-5
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-58
   PubMed Web of Science ®Google Scholar
• Kanazawa M, Watanabe S, Tana C, Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011;23:754-e332
   PubMed Web of Science ®Google Scholar
• Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Alim Pharmacol Ther 2005;22:927-34
   PubMed Web of Science ®Google Scholar
• Song GH, Leng PH, Gwee KA, Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005;54:1402-7
   PubMed Web of Science ®Google Scholar
• Saha L, Malhotra S, Rana S, A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007;41:29-32
   PubMed Web of Science ®Google Scholar
• Lu WZ, Song GH, Gwee KA, Ho KY. The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig Dis Sci 2009;54:1087-93
   PubMed Web of Science ®Google Scholar
• Szarka LA, Camilleri M, Burton D, Efficacy of on-demandasimadoline, a peripheralkappa-opioidagonist, in females with irritablebowelsyndrome. Clin Gastroenterol Hepatol 2007;5:1268-75
   PubMed Web of Science ®Google Scholar
• Sharara AI, Aoun E, Abdul-Baki H, A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-33
   PubMed Web of Science ®Google Scholar
• Lembo AZ, Ferreira SF, Ringel Nl, Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 2008;134:P-255
   Google Scholar
• Mendzelevski B, Ausma J, Chanter DO, Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol 2012;73:203-9
   PubMed Web of Science ®Google Scholar